Imatinib mesylate has antitumor activity in vitro and in vivo against neuroblastoma cell lines and xenografts characterized by a different expression of receptor tyrosine kinases. In this article, we report that imatinib tumor concentration can be independent of the administered dose and does not correlate with the antitumor effect. In xenografts, high-dose administration does not improve imatinib efficacy. In conclusion, there is no clear-cut correlation between the levels of expression for imatinib-responsive targets and the in vitro and in vivo sensitivity. This further suggests that in neuroblastoma the antitumor activity of imatinib may involve the inhibition of other tyrosine kinases and/or pathways.
Meco, D., Riccardi, A. S., Servidei, T., Brueggen, J., Gessi, M., Riccardi, R., Dominici, C., Antitumor activity of imatinib mesylate in neuroblastoma xenografts, <<CANCER LETTERS>>, 2005; 228 (1-2): 211-219. [doi:10.1016/j.canlet.2005.02.054] [http://hdl.handle.net/10807/17241]
Antitumor activity of imatinib mesylate in neuroblastoma xenografts
Meco, Daniela;Riccardi, Anna Shirley;Servidei, Tiziana;Gessi, Marco;Riccardi, Riccardo;
2005
Abstract
Imatinib mesylate has antitumor activity in vitro and in vivo against neuroblastoma cell lines and xenografts characterized by a different expression of receptor tyrosine kinases. In this article, we report that imatinib tumor concentration can be independent of the administered dose and does not correlate with the antitumor effect. In xenografts, high-dose administration does not improve imatinib efficacy. In conclusion, there is no clear-cut correlation between the levels of expression for imatinib-responsive targets and the in vitro and in vivo sensitivity. This further suggests that in neuroblastoma the antitumor activity of imatinib may involve the inhibition of other tyrosine kinases and/or pathways.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
